rna
virus
signific
sourc
morbid
mortal
human
everi
year
addit
potenti
use
virus
act
bioterror
pose
threat
nation
secur
given
pauciti
vaccin
postexposur
therapeut
mani
highli
pathogen
rna
virus
novel
treatment
badli
need
sequencebas
drug
design
develop
almost
year
prove
effect
anim
model
move
clinic
trial
import
advanc
field
includ
character
rna
interfer
mammalian
cell
chemic
modif
dramat
increas
vivo
stabil
therapeut
oligonucleotid
antisens
strategi
util
singlestrand
dna
oligonucleotid
inhibit
protein
product
mediat
catalyt
degrad
target
mrna
bind
site
mrna
essenti
translat
doublestrand
rna
oligonucleotid
known
shortinterf
rna
sirna
also
mediat
catalyt
degrad
complementari
mrna
rna
viru
infect
predic
deliveri
replic
translat
viral
rna
pathogen
present
obviou
target
rapidli
advanc
field
sequencespecif
therapeut
antisens
oligonucleotid
sirna
design
target
viral
rna
genom
viral
transcript
articl
review
current
knowledg
therapeut
applic
antisens
rna
interfer
highli
pathogen
rna
viral
infect
number
rna
virus
highli
infecti
acut
pathogen
pose
signific
threat
human
health
public
safeti
exampl
influenza
viru
infect
us
popul
year
caus
approxim
death
http
wwwcdcgovflukeyfact
pose
continu
threat
global
pandem
could
kill
million
johnson
mueller
dengu
viru
endem
tropic
region
around
world
report
infect
million
peopl
year
caus
case
dengu
hemorrhag
fever
halstead
newli
emerg
rna
virus
also
endang
public
health
evidenc
outbreak
sever
acut
respiratori
syndrom
sar
caus
novel
coron
pmo
show
efficaci
three
anim
model
warfield
et
al
mous
pmo
inhibit
ebov
vitro
protect
mice
pre
postchalleng
enterlein
et
al
sirna
guinea
pig
snalp
encapsul
sirna
l
protect
guinea
pig
challeng
geisbert
et
al
marv
sirna
vero
reduct
target
protein
amount
releas
viru
fowler
et
al
flavivirida
jev
wnv
pmo
vero
mous
singl
pmo
give
cross
protect
cell
cultur
partial
vivo
efficaci
wnv
dea
et
al
denv
pmo
bhk
conjug
pmo
inhibit
viral
replic
mechan
investig
vitro
holden
et
al
jev
sirna
mous
conjug
brain
target
sirna
given
iv
protect
mice
jev
kumar
et
al
jev
wnv
shrna
sirna
mous
inject
singl
sirna
ic
protect
mice
jev
wnv
kumar
et
al
arenavirida
veev
sirna
bhk
sirna
inhibit
multipl
strain
veev
obrien
lassa
sirna
vero
l
np
sirna
inhibit
lassa
isol
lcmv
mopeia
viru
muller
gunther
coronavirida
sar
cov
pmo
vero
conjug
pmo
tr
inhibit
cytopatholog
viral
titer
viral
spread
neuman
et
al
sirna
mous
rhesu
sirna
treatment
reduc
viral
replic
spread
along
clinic
sign
sar
anim
model
li
et
al
sirna
develop
sar
cov
sequenc
code
membran
qin
et
al
shrna
vero
shrna
orf
prevent
viral
gene
express
replic
akerstrom
et
al
orthomyxovirida
influenza
pmo
vero
mdck
conjug
pmo
inhibit
multipl
strain
influenza
cell
cultur
ge
et
al
aso
cef
chicken
aso
target
protect
chicken
lethal
infect
wu
et
al
sirna
mous
sirna
pa
np
inhibit
product
multipl
viru
subtyp
increas
surviv
tompkin
et
al
sirna
shrna
mous
sirna
shrna
given
iv
reduc
viral
titer
lung
tissu
ge
et
al
shrna
mdck
mous
shrna
target
np
given
iv
partial
protect
mice
zhou
et
al
mdck
cef
chick
egg
shrna
inhibit
cytopath
effect
viru
titer
virusinduc
apoptosi
li
et
al
oligonucleotid
inhibit
translat
mediat
rnase
hdepend
degrad
complementari
target
rna
introduct
small
doublestrand
rna
oligonucleotid
sirna
mediat
cleavag
target
transcript
activ
rna
interfer
pathway
small
hairpin
rna
shrna
express
dna
viral
vector
also
enter
rna
interfer
pathway
process
sirna
reagent
aggress
pursu
therapeut
varieti
ailment
includ
viral
infect
viral
genom
rna
viral
mrna
molecul
directli
target
aim
disrupt
viral
replic
diseas
progress
regard
continu
preclin
success
use
nucleic
acidbas
techniqu
treat
viral
infect
laboratori
anim
bennink
palmor
lee
rossi
lim
et
al
warfield
et
al
review
variou
experiment
oligonucleotidebas
therapi
describ
recent
effort
target
rna
virus
tabl
aso
singlestrand
deoxyribonucleotid
oligom
nucleotid
nucleotid
sequenc
design
complementari
target
mrna
transcript
aso
must
long
enough
confer
target
specif
form
dnarna
hybrid
suffici
stabil
howev
length
increas
greater
probabl
aso
bind
partial
complementar
nontarget
sequenc
typi
calli
specif
basepair
interact
aso
target
transcript
result
rnase
hmediat
degrad
target
rna
subsequ
reduct
protein
product
target
gene
fig
rnase
h
activ
mammalian
cell
ubiquit
constitut
thought
normal
play
role
dna
replic
transcript
busen
et
al
busen
eder
et
al
turchi
et
al
target
ribosom
entri
site
untransl
region
mrna
aso
particular
chemic
modif
discuss
inhibit
translat
absenc
mrna
degrad
unmodifi
oligonucleotid
highli
unstabl
vivo
circul
within
cell
due
rapid
nucleas
digest
therefor
aso
routin
custom
chemic
modif
increas
stabil
confer
desir
attribut
exampl
fomivirsen
vitraven
fdaapprov
aso
antivir
drug
phosphodiest
linkag
modifi
replac
nonlink
oxygen
sulfur
atom
phosphorothio
modif
fig
orr
geari
et
al
phosphorothioatemodifi
aso
poor
substrat
nucleas
thu
show
increas
stabil
increas
serum
halflif
greater
tissu
retent
although
improv
term
stabil
highli
charg
oligo
decreas
affin
target
mrna
taken
effici
cell
readili
bind
serum
intracellular
protein
may
lead
diminish
activ
offtarget
effect
trigger
complement
cascad
stein
krieg
krieg
stein
addit
modif
posit
ribos
ring
develop
increas
affin
target
mrna
provid
resist
degrad
prakash
bhat
nucleotid
modif
ethyl
moe
substrat
rnase
h
cleavag
bound
target
rna
fig
therefor
retain
properti
aso
bind
serum
protein
aso
charg
backbon
thought
sourc
toxic
case
exampl
high
dose
phosphorothioatemodifi
aso
activ
complement
cascad
possibl
interact
serum
protein
factor
h
jason
et
al
chan
et
al
effort
reduc
unwant
effect
thirdgener
aso
reagent
phosphorodiamid
morpholino
oligom
pmo
develop
ribos
ring
nucleotid
backbon
replac
morpholin
ring
fig
summerton
addit
neg
charg
intersubunit
linkag
replac
uncharg
phosphorodiamid
linkag
presenc
uncharg
nucleotid
backbon
greatli
reduc
interact
serum
cellular
protein
limit
offtarget
toxic
pmo
modif
also
confer
high
stabil
solubl
desir
qualiti
use
clinic
pmo
bind
target
mrna
sequenc
higher
affin
aso
mediat
catalyt
degrad
target
rna
transcript
via
rnase
h
summerton
instead
pmo
typic
design
target
ribosom
entri
site
aug
start
codon
splice
junction
site
critic
rna
secondari
structur
thu
reduc
target
protein
level
interf
translat
mrna
process
fig
sever
aso
compound
current
evalu
clinic
trial
treatment
varieti
ailment
includ
cancer
diabet
viral
infect
wwwclinicaltrialsgov
trial
way
studi
intraven
deliveri
aso
drug
candid
target
genasens
genta
cmyc
restenng
avi
biopharma
complet
trial
evalu
subcutan
administ
aso
target
protein
tyrosin
phosphatas
isi
isi
pharmaceut
hepat
c
viru
avi
biopharma
despit
research
effort
effect
compound
deliveri
still
major
hurdl
must
overcom
aso
compound
find
broad
util
clinic
perhap
tell
aso
drug
approv
date
fda
fomivirsen
administ
local
confin
space
eye
furthermor
despit
success
aso
clinic
use
limit
due
signific
side
effect
mercorelli
et
al
conjug
aso
cellpenetr
peptid
increasingli
common
approach
improv
cellular
uptak
pooga
et
al
debart
et
al
recent
report
demonstr
conjug
pmo
ppmo
argininerich
peptid
rxr
increas
elimin
halflif
tissu
retent
amantana
et
al
howev
literatur
reveal
consist
correl
peptid
conjug
increas
efficaci
enterlein
et
al
tilley
et
al
ppmo
gener
well
toler
anim
recipi
although
toxic
observ
dose
increas
amantana
et
al
tilley
et
al
natur
treatment
regimen
may
affect
ppmo
toxic
exampl
burrer
et
al
observ
treatmentassoci
toxic
ppmo
administ
healthi
mice
howev
ppmo
treatment
follow
viral
challeng
signific
toxic
observ
rna
interfer
rnai
endogen
molecular
pathway
play
role
antivir
defens
gene
regul
human
genom
encod
special
noncod
transcript
term
microrna
mirna
regul
express
cellular
gene
bartel
ying
et
al
first
mirna
discov
role
develop
caenorhabd
elegan
lee
et
al
reinhart
et
al
estim
mammalian
proteincod
gene
divers
cellular
process
regul
mirna
le
sage
agami
long
polyadenyl
primari
mirna
transcript
contain
hairpin
structur
sequenc
homolog
target
gene
first
process
nucleu
yield
shorter
mirna
precursor
premirna
premirna
shuttl
cytoplasm
process
dicer
yield
matur
short
doubl
strand
mirna
lee
et
al
load
rnainduc
silenc
complex
risc
guid
hybrid
target
mrna
bind
activ
risc
complex
target
transcript
lead
transcript
degrad
inhibit
translat
sontheim
rnai
pathway
wide
exploit
tool
silenc
express
specif
target
gene
experiment
therapeut
benefit
lee
sinko
rnai
pathway
activ
introduc
synthet
doublestrand
small
interf
rna
sirna
cell
altern
small
hairpin
rna
shrna
express
transfect
dna
plasmid
vector
replicationdefici
viral
vector
ie
adenoviru
lentiviru
among
other
sirna
load
directli
risc
mediat
target
hybrid
cleavag
fig
contrast
shrna
cleav
dicer
incorpor
risc
sequencebas
rule
design
sirna
molecul
optim
activ
becom
increasingli
sophist
avail
gener
research
commun
elbashir
et
al
henschel
et
al
pei
tuschl
shah
et
al
addit
predesign
sirna
shrna
express
vector
target
nearli
everi
gene
human
mous
genom
avail
commerci
sourc
vivo
use
sirna
aso
face
similar
pitfal
includ
stabil
deliveri
offtarget
effect
phosphorothio
linkag
omethyl
sugar
modif
protect
sirna
nucleas
digest
help
prevent
offtarget
stimul
type
interferon
system
sioud
pursuit
system
target
deliveri
sirna
deliv
within
liposom
conjug
antibodi
cholesterol
rna
aptam
peptid
de
fougerol
et
al
recent
report
demonstr
feasibl
organspecif
deliveri
sirna
given
intraven
kumar
et
al
author
util
abil
rabi
viru
glycoprotein
g
rvg
bind
acetylcholin
receptor
neuron
cell
peptid
rvg
show
neuron
cell
specif
conjug
sirna
enabl
deliveri
cell
type
importantli
rvgsirna
administ
mice
intraven
deliv
brain
without
accumul
spleen
liver
kumar
et
al
although
highli
success
sirna
deliveri
method
anim
model
remain
studi
whether
gener
approach
safe
human
often
cite
advantag
sirna
shrna
molecul
util
endogen
molecular
pathway
achiev
desir
effect
howev
case
could
account
observ
treatmentinduc
toxic
grimm
et
al
use
total
differ
shrna
express
adenoassoci
viru
vector
achiev
highlevel
shrna
express
mous
liver
intraven
inject
forti
seven
percent
treat
mice
die
within
month
interestingli
morbid
correl
observ
decreas
liver
mirna
level
author
demonstr
highlevel
shrna
express
satur
interfer
compon
endogen
mirna
pathway
specif
satur
may
involv
protein
occur
level
mirna
nuclear
export
contrast
system
administr
sirna
achiev
gene
silenc
liver
without
toxic
without
disrupt
liver
mirna
process
john
et
al
one
obviou
explan
introduc
sirna
bypass
earli
process
step
mirna
shrna
load
directli
risc
complex
john
et
al
demonstr
sirnadepend
silenc
liverexpress
transcript
without
decreas
liver
mirna
level
disrupt
liver
mirna
targetgen
express
importantli
posit
safeti
result
achiev
phase
ii
clinic
trial
local
deliv
sirna
treatment
includ
bevasiranib
sirna
intravitr
inocul
target
vascular
endotheli
growth
factor
acuiti
pharmaceut
intranas
deliv
product
target
transcript
nucleocapsid
protein
respiratori
syncyti
viru
alnylam
pharmaceut
rna
viru
infect
requir
deliveri
viral
genom
cell
transcript
viral
mrna
subsequ
translat
viral
protein
aid
genom
replic
viral
assembl
bud
target
viral
rna
sequenc
aso
sirna
conceptu
appeal
strategi
treat
rna
viru
infect
sever
reason
first
prevent
synthesi
even
one
critic
viral
protein
could
potenti
disrupt
viral
life
cycl
secondli
sequenc
specif
aso
sirna
compound
potenti
allow
viral
gene
target
without
affect
host
gene
thu
decreas
elimin
unwant
side
effect
addit
target
viral
sequenc
requir
understand
gene
function
feasibl
use
aso
sirna
disrupt
rna
viru
gene
express
first
demonstr
use
rou
sarcoma
viru
respiratori
syncyti
viru
respect
stephenson
zamecnik
bitko
barik
viral
genom
sequenc
avail
easili
acquir
allow
research
rapidli
design
test
novel
nucleic
acidbas
sequencespecif
antivir
reagent
support
approach
extens
rapidli
expand
record
use
antisens
rnai
target
virus
therapeut
benefit
recent
investig
sequencebas
reagent
highli
pathogen
rna
virus
discuss
ebola
ebov
marburg
marv
virus
singlestrand
negativesens
kb
rna
genom
code
seven
protein
viral
replic
transcript
depend
complex
nucleoprotein
np
rna
polymeras
l
involv
bud
matur
virion
cell
surfac
glycoprotein
gp
found
embed
lipid
bilay
surround
nucleocapsid
filovirus
list
categori
bioterror
agent
cdc
must
handl
biosafeti
level
condit
virus
caus
sever
hemorrhag
fever
human
mortal
rate
thacker
feldmann
current
vaccin
therapeut
treat
filoviru
infect
human
inform
perspect
filoviru
drug
develop
see
articl
bausch
et
al
two
preclin
studi
publish
investig
pmo
treatment
ebov
infect
show
efficaci
anim
model
pmo
design
inhibit
translat
ebov
l
transcript
three
pmo
show
activ
use
vitro
translat
assay
reduc
viral
titer
cell
cultur
similar
studi
differ
pmo
also
reduc
viru
yield
cell
cultur
enterlein
et
al
pmo
target
conjug
argininerich
peptid
ppmo
left
unconjug
test
mous
model
ebov
infect
five
hundr
microgram
pmo
ppmo
deliv
mice
intraperiton
inject
ip
h
h
ebov
challeng
treatment
regimen
pmo
protect
mice
lethal
infect
ppmotreat
mice
surviv
similarli
mice
surviv
treat
ppmo
h
ebov
challeng
comprehens
investig
l
pmo
util
three
anim
model
test
efficaci
mice
unconjug
pmo
provid
complet
near
complet
protect
respect
deliv
ip
inject
twice
ebov
infect
importantli
combin
treatment
three
pmo
given
h
ebov
infect
provid
complet
protect
surviv
mice
develop
immun
respons
ebov
protect
subsequ
challeng
guinea
pig
maximum
efficaci
seen
combin
treatment
given
h
postchalleng
compar
treatment
singl
pmo
given
closer
challeng
probabl
due
differ
pharmacokinet
bioavail
treatment
regimen
final
antiebov
pmo
treatment
investig
rhesu
macaqu
monkey
administ
singl
pmo
combin
three
pmo
l
day
day
ebov
challeng
combin
parenter
rout
monkey
treat
singl
pmo
surviv
ebov
infect
two
four
monkey
receiv
combin
pmo
treatment
surviv
lethal
ebov
challeng
third
monkey
treatment
group
remain
avirem
succumb
secondari
bacteri
infect
addit
promis
pmo
studi
sirna
may
prove
effect
therapi
filoviru
infect
increas
serum
halflif
sirna
vivo
special
liposom
use
form
stabl
nucleic
acidlipid
particl
snalp
geisbert
et
al
snalpencapsul
sirna
ebov
l
gene
efficaci
guinea
pig
model
ebov
infect
given
daili
ip
inject
begin
h
challeng
viremia
detect
sirnatr
anim
although
two
five
sirnatr
guinea
pig
die
compar
five
five
dead
control
anim
result
could
indic
therapydepend
toxic
trial
lower
dose
snalp
l
sirna
perform
success
protect
challeng
anim
recent
sirna
also
gener
target
marv
np
transcript
fowler
et
al
sirna
effici
reduc
level
target
transcript
cotransfect
assay
marv
infect
vero
cell
expect
decreas
yield
viru
releas
vero
cell
h
infect
togeth
studi
suggest
filoviru
infect
suscept
antisens
sirnamedi
therapi
warrant
investig
therapeut
eventu
use
human
grow
consider
develop
antivir
rnaibas
drug
candid
presenc
virusencod
rna
silenc
suppressor
rsss
voinnet
although
presenc
signific
endogen
rnai
antivir
respons
mammalian
cell
still
scrutini
well
establish
plant
insect
nematod
suggest
ebov
rss
activ
protein
inhibit
shrnamedi
silenc
luciferas
express
cotransfect
assay
haasnoot
et
al
rnai
inhibit
could
attribut
interferon
ifn
antagon
effect
also
observ
vero
cell
defect
interferon
pathway
addit
function
complement
mutant
tat
protein
tat
exhibit
rss
activ
requir
viral
replic
bennass
et
al
haasnoot
et
al
tempt
specul
sirna
asopmo
treatment
target
rss
protein
encod
sequenc
whether
part
pool
individu
compound
efficaci
treatment
reduc
rss
protein
level
like
import
area
investig
near
futur
flavivirus
contain
kb
plussens
orient
singlestrand
rna
genom
encod
singl
long
polyprotein
gener
polyprotein
cleav
produc
three
structur
seven
nonstructur
protein
samuel
diamond
famili
flavivirida
contain
number
import
human
pathogen
includ
west
nile
wnv
yellow
fever
yfv
japanes
enceph
jev
dengu
denv
virus
signific
denv
infect
alreadi
cite
increas
public
health
toll
jev
describ
anoth
paper
issu
gould
et
al
report
case
wnv
infect
unit
state
alon
neuroinvas
http
wwwcdcgov
importantli
current
approv
vaccin
antivir
therapi
denv
wnv
use
human
pmo
use
inhibit
flaviviru
infect
wnv
jev
slev
denv
target
conserv
sequenc
within
untransl
region
viral
genom
dea
et
al
dea
et
al
kinney
et
al
holden
et
al
area
genom
form
critic
secondari
structur
necessari
viral
replic
khromykh
et
al
dea
et
al
identifi
peptideconjug
pmo
ppmo
target
highli
conserv
sequenc
element
exhibit
potent
antiwnv
activ
cell
cultur
subsequ
report
pmo
redesign
achiev
perfect
complementar
sequenc
element
wnv
jev
st
loui
enceph
viru
slev
dea
et
al
redesign
oligo
effect
three
virus
cell
cultur
ppmo
pmo
target
sequenc
element
test
mous
model
wnv
infect
although
mice
could
toler
higher
dose
pmo
compar
ppmo
reagent
protect
virusinfect
mice
contrast
ppmo
even
given
lower
dose
increas
surviv
improv
clinic
correl
mice
infect
wnv
one
specul
conjug
peptid
improv
cellular
uptak
pmo
way
improv
efficaci
sever
group
success
inhibit
wnv
replic
use
sirnabas
approach
kachko
et
al
ong
et
al
importantli
target
highli
conserv
sequenc
progress
made
design
antisens
rnaibas
therapi
protect
mice
challeng
multipl
flavivirus
screen
sever
sirna
jev
genom
kumar
et
al
identifi
sirna
target
envelop
protein
e
provid
signific
protect
jev
infect
cell
cultur
singl
dose
especif
shrnaexpress
neurotrop
lentiviru
abl
provid
complet
protect
mice
surviv
lethal
jev
challeng
mice
administ
intracrani
ic
inject
although
approach
success
protect
mice
jev
lentivirusbas
therapi
may
hard
time
find
way
clinic
due
safeti
concern
stem
viral
integr
sirna
may
offer
better
choic
transient
natur
effect
eas
dose
regimen
optim
one
hundr
percent
mice
inject
ic
lipidencapsul
sirna
target
e
min
h
challeng
protect
lethal
jev
infect
importantli
author
abl
design
sirna
nearperfect
homolog
region
e
gene
jev
wnv
ic
inject
min
h
challeng
provid
almost
complet
protect
jev
wnv
kumar
et
al
demonstr
vivo
efficaci
intraven
iv
administ
sirna
jev
peptid
deriv
glycoprotein
rabi
viru
rvg
enabl
brainspecif
deliveri
conjug
sirna
given
iv
treatment
rvgconjug
sirna
e
protein
initi
h
challeng
repeat
daili
day
treatment
regimen
induc
type
ifn
respons
protect
mice
lethal
enceph
addit
inform
antivir
therapi
jev
avail
issu
gould
et
al
like
filovirus
flavivirus
sever
virus
famili
arenavirida
caus
sever
hemorrhag
fever
human
includ
niaid
categori
prioriti
pathogen
lassa
junin
machupo
virus
gunther
lenz
genom
arenavirus
compos
two
singlestrand
rna
segment
harbor
two
gene
one
sens
one
antisens
direct
larger
rna
segment
code
zincbind
protein
z
viral
polymeras
l
smaller
segment
code
glycoprotein
precursor
gpc
nucleoprotein
np
termini
rna
segment
highli
conserv
among
arenavirus
act
promot
replic
transcript
includ
viral
mrna
transcript
gunther
lenz
sequenc
provid
attract
target
sequencebas
therapi
recent
report
sirna
target
conserv
termini
sequenc
np
l
gpcz
investig
muller
gunther
sirna
np
l
show
activ
vitro
lassa
viru
minigenom
replicon
system
importantli
sirna
inhibit
replic
five
differ
lassa
viru
isol
along
two
arenavirus
lymphocyt
choriomening
viru
mopeia
cell
cultur
vero
cell
transfect
sirna
h
later
infect
variou
arenavirus
cell
cultur
supernat
harvest
viral
titer
measur
immunolog
focu
assay
inform
treatment
lassa
fever
see
articl
khan
et
al
venezuelan
equin
enceph
viru
veev
mosquitoborn
envelop
rna
viru
genu
alphaviru
found
central
south
america
extens
studi
laboratori
weaver
et
al
positivesens
singlestrand
rna
genom
code
seven
gene
four
nonstructur
protein
three
structur
protein
capsid
although
lethal
human
infect
rare
acut
enceph
develop
exposur
veev
also
easili
transmit
aerosol
consid
possibl
agent
bioterror
current
licens
vaccin
antivir
therapi
human
use
sirna
investig
abil
inhibit
veev
replic
vitro
obrien
four
individu
sirna
design
target
sequenc
gene
conserv
six
veev
strain
pool
four
sirna
transfect
bhk
cell
defect
ifn
product
antivir
activ
observ
veev
strain
test
although
inhibit
viral
replic
transient
studi
rais
possibl
pool
sirna
could
use
target
multipl
genet
strain
particular
viru
sar
emerg
atyp
pneumonia
guangdong
provinc
china
late
quickli
spread
southeast
asia
north
america
eventu
appear
countri
caus
death
satija
lal
death
occur
approxim
infect
individu
follow
flulik
symptom
includ
fever
malais
dri
cough
lead
acut
respiratori
distress
diffus
alveolar
damag
intens
research
effort
identifi
novel
coronaviru
sar
cov
caus
agent
sar
peiri
et
al
rota
et
al
like
coronavirus
rna
genom
sar
cov
larg
kb
singlestrand
posit
sens
orient
cap
polyadenyl
neuman
et
al
describ
design
test
peptideconjug
pmo
complementari
sever
region
sar
cov
genom
target
region
includ
aug
start
codon
replicas
gene
orf
orf
ribosom
frameshift
point
utr
transcript
regulatori
sequenc
tr
utr
pmo
design
target
tr
consensu
sequenc
disrupt
secondari
structur
form
point
genom
vero
cell
treat
pmo
infect
sar
cov
test
pmo
reduc
cytopath
effect
viral
infect
reduc
viral
yield
viral
spread
inhibit
viral
genom
rna
synthesi
number
preclin
studi
complet
investig
abil
sirna
prevent
sar
cov
replic
cytopath
effect
recent
review
wu
chan
experi
target
sever
region
sar
cov
genom
demonstr
sirna
shrna
reduc
target
gene
express
viral
rna
level
viral
yield
zheng
et
al
conduct
initi
vitro
screen
sirna
cover
entir
sar
cov
genom
identifi
two
promis
sirna
target
spike
proteincod
region
region
sirna
evalu
vivo
sirna
administ
combin
intranas
rhesu
macaqu
intranas
challeng
sar
cov
li
et
al
sirna
treatment
regimen
success
repress
viral
replic
spread
lung
prevent
develop
clinic
sign
sar
although
sirna
treatment
complet
elimin
presenc
sar
cov
efficaci
demonstr
reduc
viral
load
oropharyng
swab
lung
tissu
section
less
sever
diffus
alveolar
damag
diminish
fever
treatmentassoci
toxic
safeti
concern
li
et
al
influenza
virus
contain
eight
segment
singlestrand
neg
sens
genom
rna
code
known
protein
cheung
poon
multipl
subtyp
influenza
viru
exist
base
antigen
variat
envelopeassoci
hemagglutinin
ha
neuramidas
na
protein
ie
vaccin
protect
individu
specif
viral
subtyp
emerg
novel
strain
pose
risk
deadli
pandem
johnson
mueller
highli
virul
avian
influenza
viru
also
infect
human
current
viru
spread
easili
person
person
acquisit
abil
consequ
influenza
pandem
could
truli
devast
sinc
aso
investig
potenti
therapi
influenza
viru
infect
antisens
phosphodiest
phosphorothio
oligo
success
decreas
express
viral
protein
pa
cell
cultur
hatta
et
al
hatta
et
al
phosphorothio
oligo
target
also
shown
efficaci
vivo
lipid
encapsul
aso
target
aug
start
codon
given
iv
protect
mice
lethal
challeng
influenza
mizuta
et
al
treatment
effect
reduc
viral
rna
level
mous
lung
decreas
viral
titer
lung
limit
damag
lung
tissu
recent
report
omethylmodifi
aso
target
deliv
intranas
protect
chicken
lethal
infect
wu
et
al
pmo
also
design
found
inhibit
multipl
strain
influenza
viru
ge
et
al
peptideconjug
pmo
ppmo
design
bind
aug
start
codon
region
four
gene
pa
np
addit
ppmo
design
target
four
termin
region
np
gene
interrupt
viral
rnarna
interact
requir
rna
synthesi
six
eight
ppmo
success
inhibit
product
vero
cell
base
result
two
ppmo
test
activ
panel
influenza
subtyp
includ
highli
pathogen
notabl
pretreat
ppmo
target
start
codon
termin
region
np
effect
inhibit
growth
mdck
cell
postinfect
protocol
also
show
success
ge
et
al
influenza
aspecif
sirna
proven
efficaci
mice
protocol
preferenti
deliv
nucleic
acid
lung
sirna
specif
np
pa
ge
et
al
shrna
target
np
zhou
et
al
administ
intraven
complex
cation
polym
pei
studi
sirna
shrna
treatment
reduc
viral
titer
lung
tissu
shrna
np
also
increas
surviv
mice
infect
influenza
strain
anoth
group
also
demonstr
sirna
target
pa
np
reduc
influenza
viru
product
lung
infect
mice
increas
surviv
tompkin
et
al
combin
treatment
pa
np
sirna
provid
protect
lethal
challeng
importantli
antivir
activ
seen
multipl
strain
influenza
includ
detect
serum
lung
tissu
homogen
mice
treat
sirna
evid
observ
antivir
effect
due
ifn
product
addit
inform
treat
season
avian
influenza
see
review
beigel
bray
base
preclin
studi
antisens
sirnabas
antivir
compound
appear
hold
great
deal
promis
increasingli
find
way
fda
approv
process
clinic
howev
deliveri
remain
signific
challeng
mention
fdaapprov
aso
drug
administ
local
recent
report
peptidemedi
organspecif
deliveri
sirna
system
administr
import
advanc
deliveri
method
potenti
increas
efficaci
mani
aso
sirna
compound
develop
system
postexposur
treatment
regimen
critic
success
widespread
use
compound
expect
efficaci
drug
candid
improv
aso
sirna
design
rule
becom
even
better
understood
entir
viral
genom
systemat
screen
appropri
target
